Zogenix Advances Abuse-Deterrent Formulations of Hydrocodone
Zogenix, Inc., a pharmaceutical company specializing in drugs to treat pain and central nervous system disorders, outlined its plans fot develop abuse-deterrent formulations of Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII. Zohydro ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The company is developing two distinct approaches for abuse-deterrent formulations of Zohydro ER. Following a recent meeting with the
If approved, this new formulation could be available to prescribers in early 2015. The company will continue to characterize the product’s abuse deterrent properties with the goal of further amending the labeling for Zohydro ER extended-release capsules in 2015 to include abuse deterrence claims consistent with the
Source: Zogenix